InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.038 0.007 (22.58%)+
Announcement
Release
30 Apr 2026 9:13AM
Price at Release
$0.031
Full Release
download
Summary
Patrys Limited has positioned itself for a clinical transition as it advances its lead program RLS-2202, following the acquisition of Reliis Pty Ltd. The company is progressing towards initiating Phase 1A clinical trials in the second half of 2026 and has commenced regulatory processes in the US. Patrys has also strengthened its leadership team with the appointment of a new CEO and additional directors. Financially, Patrys secured A$3.2 million through a placement to fund upcoming milestones, reporting a cash balance of A$1.196 million at quarter-end.
Key Points
  • Patrys Limited completed the acquisition of Reliis Pty Ltd.
  • The lead program RLS-2202 (injectable quetiapine) is advancing towards Phase 1A clinical trials.
  • The company is working on its deoxymab platform and assessing strategic opportunities.
  • Engineering batch manufacturing began at BioCina for clinical supply preparation.
  • US regulatory engagement has started, preparing for FDA submissions.
  • Patrys appointed Dr. Samantha South as CEO and added two Non-Executive Directors.
  • The company completed a A$3.2 million Placement to support clinical and regulatory milestones.
  • Cash balance at the end of the quarter was A$1.196 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.